Treatment of Bronchial Asthma with Unani medicine Habb-e- Hindi Zeeqi

Clinical Validation of Unani Pharmocopoeial Formulation Habb-e-Hindi Zeeqi in Zeequn Nafas (Bronchial Asthma)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/02/017799

Enrollment

240

Registered

2019-02-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

Intervention1: Habb-e-Hindi Zeeqi: One tablet (125mg) orally twice daily with lukewarm water for 4 weeks Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Males and females of 18-65 years 2. Objective evidence for reversible airway obstruction (>=12% and >=200 mL change in FEV1 and/or a 25% and 60 L/min change in PEFR) either spontaneously or after treatment 3. Asthma for at least 6 months before enrollment

Exclusion criteria

Exclusion criteria: The patients of Zeeq-un-Nafas (Bronchial Asthma) with following conditions will be excluded from the study: 1. FEV1/FVC ratio 2. Pregnant and lactating mother 3. Patient with other Respiratory Tract Infections, tuberculosis and malignancy. 4. Patient with co-morbidities, Diabetes Mellitus, Hepatic and Renal Insufficiency. 5. Patient with regular use of oral or systemic corticosteroids for conditions other than Asthma.

Design outcomes

Primary

Measure	Time frame
Improvement in sign and symptoms of Zeequn Nafas (Bronchial Asthma)Timepoint: 4 weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026